Background: Serum levels of 25-OH vitamin D3 (vitamin D) have been shown to be prognostic for
disease-free survival in patients with breast cancer. We investigated the predictive value of these levels
for pathological response after neoadjuvant chemotherapy in patients with breast cancer taking part in
the NEOZOTAC phase-III trial. Additionally, the effect of chemotherapy on vitamin D levels was studied.